Wealth Dimensions Group Ltd. Has $222,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealth Dimensions Group Ltd. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 402 shares of the medical research company’s stock after purchasing an additional 32 shares during the quarter. Wealth Dimensions Group Ltd.’s holdings in Thermo Fisher Scientific were worth $222,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Waycross Partners LLC grew its stake in shares of Thermo Fisher Scientific by 12.6% during the 2nd quarter. Waycross Partners LLC now owns 25,014 shares of the medical research company’s stock worth $13,833,000 after acquiring an additional 2,791 shares during the period. Fairfield Financial Advisors LTD purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $93,000. Quilter Plc grew its position in shares of Thermo Fisher Scientific by 4.3% in the second quarter. Quilter Plc now owns 215,366 shares of the medical research company’s stock valued at $119,097,000 after purchasing an additional 8,890 shares in the last quarter. Rathbones Group PLC raised its stake in shares of Thermo Fisher Scientific by 5.5% during the 2nd quarter. Rathbones Group PLC now owns 722,412 shares of the medical research company’s stock valued at $399,494,000 after purchasing an additional 37,954 shares during the period. Finally, Plato Investment Management Ltd increased its position in shares of Thermo Fisher Scientific by 4.4% during the second quarter. Plato Investment Management Ltd now owns 7,024 shares of the medical research company’s stock valued at $3,884,000 after buying an additional 296 shares during the period. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Evercore ISI lowered their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Royal Bank of Canada upped their target price on Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. TD Cowen boosted their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Stifel Nicolaus raised their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $630.41.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Marc N. Casper sold 6,300 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,548,375.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The disclosure for this sale can be found here. Insiders sold a total of 23,084 shares of company stock valued at $14,094,292 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.5 %

Shares of NYSE TMO opened at $611.17 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The firm’s fifty day moving average is $592.10 and its 200 day moving average is $580.22. The company has a market cap of $233.29 billion, a price-to-earnings ratio of 39.20, a PEG ratio of 2.86 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same period last year, the company earned $5.15 EPS. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.